How I treat myelofibrosis

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Myelofibrosis (MF) is a stem cell disorder characterized by clonal myeloproliferation, abnormal cytokine release, and bone marrow fibrosis.
• The molecular pathogenesis of MF is complex, involving acquired mutations affecting kinase signaling pathways and epigenetic regulators.

Purpose of the Study:

• To review the molecular pathogenesis of myelofibrosis.
• To discuss current prognostication tools and risk-adapted treatment strategies for MF.

Main Methods:

• Literature review of molecular pathogenesis in myelofibrosis.
• Analysis of the Dynamic International Prognostic Scoring System-plus (DIPSS-plus) for prognostication.
• Discussion of various treatment modalities including pharmacotherapy, stem cell transplantation, and other interventions.

Main Results:

• Key mutations (JAK2, MPL, LNK, TET2, ASXL1, EZH2) contribute to MF pathogenesis through kinase hyperactivation or epigenetic dysregulation.
• The DIPSS-plus model stratifies primary MF patients into risk groups with distinct survival outcomes.
• Treatment options range from observation to JAK inhibitors, stem cell transplantation, and palliative care.

Conclusions:

• Understanding MF molecular drivers is crucial for developing targeted therapies.
• Risk stratification is essential for guiding personalized treatment decisions in myelofibrosis.
• A comprehensive approach integrating molecular insights and prognostic data optimizes patient management.